JUBLPHARMA - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 2.9
| Stock Code | JUBLPHARMA | Market Cap | 14,761 Cr. | Current Price | 927 ₹ | High / Low | 1,250 ₹ |
| Book Value | 141 ₹ | Dividend Yield | 0.54 % | ROCE | 2.91 % | ROE | 1.04 % |
| Face Value | 1.00 ₹ | DMA 50 | 904 ₹ | DMA 200 | 981 ₹ | Chg in FII Hold | -0.06 % |
| Chg in DII Hold | 0.40 % | PAT Qtr | 6.60 Cr. | PAT Prev Qtr | -48.0 Cr. | RSI | 59.3 |
| MACD | 19.7 | Volume | 66,902 | Avg Vol 1Wk | 1,30,628 | Low price | 784 ₹ |
| High price | 1,250 ₹ | Debt to equity | 0.02 | 52w Index | 30.6 % | Qtr Profit Var | 154 % |
| EPS | 1.23 ₹ | Industry PE | 30.1 |
Financials: Jubilant Pharmova (JUBLPHARMA) shows weak fundamentals with ROCE at 2.91% and ROE at 1.04%. EPS of ₹1.23 is very low, though quarterly PAT improved to ₹6.60 Cr. from a loss of ₹48.0 Cr. Debt-to-equity ratio of 0.02 reflects a nearly debt-free balance sheet.
Valuation: P/E ratio is not meaningful due to weak earnings, while industry average stands at 30.1. PEG ratio unavailable, limiting growth-adjusted valuation insights. Dividend yield of 0.54% adds minor investor appeal.
Business Model: Jubilant Pharmova operates in pharmaceuticals and life sciences, with strengths in diversified product lines. Competitive advantage lies in niche pharma segments, but profitability remains under pressure.
Entry Zone: Reasonable entry between ₹900–₹930 near DMA 50 (₹904). Long-term holding requires caution due to weak fundamentals and earnings volatility.
Positive
- PAT recovery from a loss (-₹48 Cr.) to profit (+₹6.6 Cr.)
- Debt-to-equity ratio of 0.02 reflects strong balance sheet stability
- Dividend yield of 0.54% adds modest income support
- Institutional inflows (DII +0.40%) show domestic confidence
Limitation
- Very weak ROE (1.04%) and ROCE (2.91%) indicate poor efficiency
- EPS of ₹1.23 reflects weak profitability
- P/E ratio not meaningful due to low earnings
- RSI at 59.3 suggests nearing overbought territory
Company Negative News
- Earnings volatility with weak profitability base
- Decline in foreign institutional holdings (-0.06%)
Company Positive News
- PAT recovery from losses highlights operational improvement
- Technical indicators (MACD 19.7) show bullish bias
- Domestic institutional inflows (+0.40%) add support
Industry
- Pharma sector trades at P/E of 30.1, highlighting Jubilant Pharmova’s weak relative valuation
- Industry outlook remains positive with healthcare demand, but company-specific fundamentals lag
Conclusion
Jubilant Pharmova presents weak fundamentals with poor efficiency metrics and volatile earnings, though balance sheet stability and PAT recovery provide some support. Entry around ₹900–₹930 offers speculative opportunity. Long-term investors should monitor profitability recovery and valuation normalization before committing.
Would you like me to extend this into a peer benchmarking overlay comparing Jubilant Pharmova against peers like Sun Pharma, Dr. Reddy’s, and Cipla, so you can evaluate relative valuation and efficiency in a modular HTML format?